Skip to main content
. 2021 Jul 16;65(8):e00508-21. doi: 10.1128/AAC.00508-21

FIG 2.

FIG 2

Reduction of MRSA bioburden in kidney with LSVT-1701 in combination with daptomycin (Dap). Open circles, individual bioburdens; filled circles, mean bioburdens; error bars, standard deviations; dashed line, limit of experimental sterility. Values are mean log10 CFU/g tissue ± standard deviations (sterilized tissues/total tissues). *, P < 0.05 for LSVT-1701 treatment groups compared to untreated control; @, P < 0.05 for LSVT-1701 treatment groups compared to daptomycin alone; #, P < 0.05 for LSVT-1701 32.5 mg/kg i.v. QD for 4 days compared to i.v. QD for 2 days and single dose; $, P < 0.05 for LSVT-1701 50 mg/kg i.v. QD for 4 days compared to single dose; %, P < 0.05 for LSVT-1701 50 mg/kg i.v. QD for 4 days compared to 32.5 mg/kg i.v. QD for 2 days and single dose.